After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for BridgeBio Pharma Inc (BBIO) shows that investor sentiment remained same, with the stock’s consolidated last price to $38.70. The BridgeBio Pharma Inc has recorded 27,550 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
BridgeBio Pharma Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of BridgeBio Pharma Inc is $6.73B. A total of 1.41 million shares were traded on the day, compared to an average of 1.57M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, BBIO has seen 3 BUY and 2 SELL insider trades, representing the acquisition of 108,924 and the disposition of 4,216 shares. Over the last 12 months, there were 13 BUYs and 29 SELLs from insiders. Insiders purchased 514,221 shares during that period but sold 2,627,138.
In the most recent transaction, MCCORMICK FRANK sold 100,000 shares of BBIO for 42.06 per share on Dec 26. After the transaction, the Director now owns 627,689 company shares. In a previous transaction on Dec 18, Scott Randal W. sold 2,000 shares at 40.00 per share. BBIO shares that Director owns now total 9,000.
Among the insiders who sold shares, Valantine Hannah disposed of 2,915 shares on Dec 15 at a per-share price of $36.12. This resulted in the Director holding 1,764 shares of BBIO after the transaction. In another insider transaction, Scott Randal W. sold 2,500 shares at $29.40 per share on Dec 01. Company shares held by the Director now total 11,000.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, BBIO has a high of $44.32 and a low of $7.78.
As of this writing, BBIO has an earnings estimate of -$0.92 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.64 per share and a lower estimate of -$1.16. The company reported an EPS of -$0.98 in the last quarter, which was -18.10% lower than expectations of -$0.83.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$6.93, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.80.
